Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system

Histopathology

Volumn 63, Issue 5, 2013, Pages 640-648

  Lu, Su Hsi ^a   Yuan, Ray Hwang ^b   Chen, Yu Ling ^a   Hsu, Hey Chi ^a,b   Jeng, Yung Ming ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Annexin A10; Cancer of an unknown primary site; Immunohistochemistry

Indexed keywords

ANNEXIN; ANNEXIN A10; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BRUNNER GLAND; CANCER SCREENING; CARCINOMA IN SITU; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DUODENUM; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PANCREATOBILIARY SYSTEM ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TRANSITIONAL CELL CARCINOMA; UPPER GASTROINTESTINAL TRACT ADENOCARCINOMA; UROTHELIUM;

ANNEXIN A10; CANCER OF AN UNKNOWN PRIMARY SITE; IMMUNOHISTOCHEMISTRY;

ADENOCARCINOMA; ANNEXINS; BILIARY TRACT NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885425490     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12229     Document Type: Article

References (19)

1. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol. 2007; 46; 592-601.
2. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur. J. Cancer 2002; 38; 1810-1812.
3. Nadji M, Tabei SZ, Castro A, Chu TM, Morales AR. Prostatic-specific antigen; an immunohistologic marker for prostatic neoplasms. Cancer 1981; 48; 1229-1232.
4. Fabbro D, Di Loreto C, Stamerra O, Beltrami CA, Lonigro R, Damante G. TTF-1 gene expression in human lung tumours. Eur. J. Cancer 1996; 32A; 512-517.
5. Gerke V, Moss SE. Annexins; from structure to function. Physiol. Rev. 2002; 82; 331-371.
6. Violette SM, King I, Browning JL, Pepinsky RB, Wallner BP, Sartorelli AC. Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J. Cell. Physiol. 1990; 142; 70-77.
7. Masaki T, Tokuda M, Ohnishi M et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996; 24; 72-81.
8. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J. Pathol. 2008; 216; 131-140.
9. Kim J, Kim MA, Jee CD, Jung EJ, Kim WH. Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int. J. Cancer 2009; 125; 1842-1850.
10. Kim JK, Kim PJ, Jung KH et al. Decreased expression of annexin A10 in gastric cancer and its overexpression in tumour cell growth suppression. Oncol. Rep. 2010; 24; 607-612.
11. Lu SH, Chen YL, Shun CT et al. Expression and prognostic significance of gastric-specific annexin A10 in diffuse- and intestinal-type gastric carcinoma. J. Gastroenterol. Hepatol. 2011; 26; 90-97.
12. Shimizu T, Kasamatsu A, Yamamoto A et al. Annexin A10 in human oral cancer: biomarker for tumoural growth via G1/S transition by targeting MAPK signaling pathways. PLoS One 2012; 7; e45510.
13. Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 2002; 62; 5999-6005.
14. Köllermann J, Schlomm T, Bang H et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur. Urol. 2008; 54; 1314-1323.
15. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am. J. Surg. Pathol. 2005; 29; 359-367.
16. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br. J. Cancer 2009; 101; 287-294.
17. Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 2007; 131; 1561-1567.
18. Liu SH, Lin CY, Peng SY et al. Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am. J. Pathol. 2002; 160; 1831-1837.
19. Peng SY, Ou YH, Chen WJ et al. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int. J. Oncol. 2005; 26; 1053-1061.